Portal Biotech

Portal Biotech is a Cambridge-based biotech firm founded in 2018, transitioning from its initial focus on cell culture media to a cutting-edge single-molecule proteomics platform. The company leverages proprietary nanopore technology, evolved from academic research, to sequence and characterize proteins and peptides with high sensitivity, offering bench-top instruments and services. This positions Portal to address critical gaps in proteomic analysis for drug discovery and biopharmaceutical development, competing in the rapidly growing next-generation protein sequencing market.

Nanopore-based platform for single-molecule protein and peptide sequencing and characterization. It uses engineered biological nanopores to detect electrical signatures of molecules as they pass through, coupled with machine learning algorithms for decoding. Capable of full-length protein analysis, peptide spectrometry, and small-molecule detection.

Portal operates in the emerging field of next-generation protein sequencing, competing directly with other nanopore-based startups like Quantum-Si and Nautilus Biotechnology, as well as companies developing alternative single-molecule methods. It also competes indirectly with the dominant mass spectrometry industry (Thermo Fisher, Bruker, Waters) and immunoassay platforms. Its key differentiators are the focus on full-length, intact protein analysis and a bench-top form factor.